盐酸伐洛匹韦：一种丙型肝炎病毒的特异性聚合酶抑制剂。

Valopicitabine dihydrochloride:a specific polymerase inhibitor of hepatitis C virus.

作者信息

Toniutto Pierluigi, Fabris Carlo, Bitetto Davide, Fornasiere Ezio, Rapetti Rachele, Pirisi Mario

机构信息

University of Udine, Internal Medicine, Medical Liver Transplantation Unit, DPMSC, Piazzale SM della Misericordia 1, Udine 33100, Italy.

出版信息

Curr Opin Investig Drugs. 2007 Feb;8(2):150-8.

PMID:17328231

Abstract

Idenix Pharmaceuticals Inc and Novartis AG are codeveloping valopicitabine dihydrochloride, a once-daily oral nucleoside for the potential treatment of HCV infection. In January 2005, a phase IIa clinical trial comparing valopicitabine dihydrochloride with pegylated IFN in treatment-naive HCV patients was ongoing, in addition to a phase IIb trial in patients that had previously failed pegylated IFN and ribavirin combination therapy. In January 2006, an international phase III trial in treatment-refractory patients was planned for the first half of the year, with a phase III trial in treatment-naive individuals planned for the second half of the year.

摘要

艾迪尼克斯制药公司（Idenix Pharmaceuticals Inc）和诺华公司（Novartis AG）正在联合开发二盐酸缬草酸胞苷，这是一种每日服用一次的口服核苷，用于潜在治疗丙型肝炎病毒（HCV）感染。2005年1月，一项将二盐酸缬草酸胞苷与聚乙二醇化干扰素（pegylated IFN）进行对比的IIa期临床试验正在初治HCV患者中进行，此外还有一项针对先前聚乙二醇化干扰素和利巴韦林联合治疗失败患者的IIb期试验。2006年1月，计划于当年上半年在难治性患者中开展一项国际III期试验，下半年计划在初治个体中开展一项III期试验。